A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors Including RET Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-001)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumors, Medullary Thyroid Cancer, And Other Tumors With Ret Activation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients with a locally advanced or metastatic solid tumor who: • have progressed on or are intolerant to standard therapy, or • no standard therapy exists, or • in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or • decline standard therapy. 2) Prior MKI(s) with anti-RET activity are allowed. However, prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]) is prohibited 3) Archived tumor tissue sample available.

You may not be eligible for this study if the following are true:

  • 1) Phase 2, Cohorts 1-4, an additional validated oncogenic driver that could cause resistance to LOXO-292 treatment. 2) Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]) 3) Investigational agent or anticancer therapy within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292. In addition, no concurrent investigational anti-cancer therapy is permitted. Refer to the Protocol for allowable concurrent therapies 4) Major surgery (excluding placement of vascular access) within 4 weeks prior to planned start of LOXO-292.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.